+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Wilson Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 136 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5969762
The 7 major Wilson disease markets reached a value of US$ 317.2 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 428.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.39% during 2023-2034.

The Wilson disease market has been comprehensively analyzed in this report titled "Wilson Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Wilson disease is a rare genetic disorder that causes copper to accumulate in the body, particularly in the liver, brain, and eyes. The condition is caused by a mutation in the ATP7B gene, which is responsible for regulating the body's copper metabolism. The symptoms of this ailment include fatigue, lack of appetite, abdominal pain, yellowish whites of the eye, golden-brown eye discoloration, fluid buildup in the legs or abdomen, difficulty with speech, swallowing, or physical coordination, uncontrolled movements, muscle stiffness, etc. Individuals suffering from Wilson disease may also experience psychiatric problems like depression and anxiety. The diagnosis of this illness relies on an evaluation of the patient's symptoms, medical history, and eye examination using a slit lamp. The healthcare provider may also perform various diagnostic tests and procedures, including blood workups, urinalysis, genetic testing, etc., to determine the possible causes of underlying indications.

The increasing cases of autosomal recessive disorder, causing gene variations and chromosomal abnormalities, are primarily driving the Wilson disease market. In addition to this, the widespread adoption of copper chelation therapy with trientine and penicillamine to reduce copper levels in blood and prevent further organ damage is also propelling the market growth. Moreover, numerous pharmaceutical companies are focusing on developing effective heavy metal toxicity medications with a lower frequency of side effects and higher bioavailability. This, in turn, is acting as a significant growth-inducing factor. Additionally, the inflating demand for zinc acetate in maintenance therapy that can prevent the absorption of copper into the bloodstream from food, thereby prohibiting excessive copper buildup, is further creating a positive outlook for the market. Apart from this, the emerging popularity of anion exchange chromatography-triple quadrupole coupled with mass spectrometry for simple ceruloplasmin quantification and more accurate determination of copper levels in the body is positively influencing the market growth. Moreover, the ongoing developments in gene therapy using adeno-associated vectors, which can transduce both quiescent and replicating cell population, are expected to drive the Wilson disease in the coming years.

This report provides an exhaustive analysis of the Wilson disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Wilson disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Wilson disease market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the Wilson disease market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the Wilson disease market

Competitive Landscape:

This report also provides a detailed analysis of the current Wilson disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the Wilson disease market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the Wilson disease market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the Wilson disease market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of Wilson disease across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Wilson disease by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Wilson disease by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with Wilson disease across the seven major markets?
  • What is the size of the Wilson disease patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of Wilson disease?
  • What will be the growth rate of patients across the seven major markets?

Wilson Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for Wilson disease drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Wilson disease market?
  • What are the key regulatory events related to the Wilson disease market?
  • What is the structure of clinical trial landscape by status related to the Wilson disease market?
  • What is the structure of clinical trial landscape by phase related to the Wilson disease market?
  • What is the structure of clinical trial landscape by route of administration related to the Wilson disease market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Wilson Disease - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Wilson Disease - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Wilson Disease - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 Wilson Disease - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Wilson Disease - Unmet Needs10 Wilson Disease - Key Endpoints of Treatment
11 Wilson Disease - Marketed Products
11.1 List of Wilson Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Cuprior (Trientine tetrahydrochloride) - Orphalan
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Wilzin (Zinc acetate) - Teva Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Wilson Disease - Pipeline Drugs
12.1 List of Wilson Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 UX701 - Ultragenyx Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VTX801 - Vivet Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Wilson Disease - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Wilson Disease - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Wilson Disease - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Wilson Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Wilson Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Wilson Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Wilson Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Wilson Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Wilson Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Wilson Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Wilson Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Wilson Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Wilson Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Wilson Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Wilson Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Wilson Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Wilson Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Wilson Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Wilson Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Wilson Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Wilson Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Wilson Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Wilson Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Wilson Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Wilson Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Wilson Disease - Access and Reimbursement Overview
16 Wilson Disease - Recent Events and Inputs From Key Opinion Leaders
17 Wilson Disease Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Wilson Disease Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information